Cathie Wood’s ARK Invest Buys Over 750,000 Shares of Ginkgo Bioworks
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge buy on Tuesday. Specifically, this fund bought roughly $7.3 million worth of Ginkgo Bioworks Holdings Inc. (NYSE: DNA), as the prices of this fund was down slightly on Tuesday.
ARK Innovation ETF (NYSEARCA: ARKK) bought 764,703 shares of Ginkgo Bioworks. At Tuesday’s closing price, this would have valued the sale at roughly $7.3 million. Even though this is a small fraction of their total holdings, every little bit counts. The Innovation ETF is down over 23% in the past year.
Check out all the ARK Invest purchases for Tuesday as well:
| Fund | Ticker | Name | Shares |
|---|---|---|---|
| ARKF | TCSLI | TCS GROUP | 73,600 |
| ARKF | DSYSJ | DISCOVERY | 29,478 |
| ARKG | VCYT | VERACYTE | 45,700 |
| ARKG | SLGC | SOMALOGIC | 187,013 |
| ARKG | SDGR | SCHRODINGER | 12,216 |
| ARKG | QSI | QUANTUM-SI | 51,318 |
| ARKG | PSNL | PERSONALIS | 100,496 |
| ARKG | NTLA | INTELLIA THERAPEUTICS | 20,655 |
| ARKG | MASS | 908 DEVICES | 20,047 |
| ARKG | FATE | FATE THERAPEUTICS | 196,581 |
| ARKG | ACCD | ACCOLADE | 116,240 |
| ARKG | BLI | BERKELEY LIGHTS | 44,000 |
| ARKK | SSYS | STRATASYS | 72,471 |
| ARKK | NVTA | INVITAE | 18,000 |
| ARKK | NTLA | INTELLIA THERAPEUTICS | 8,433 |
| ARKK | MTLS | MATERIALISE | 32,775 |
| ARKK | DNA | GINKGO BIOWORKS | 764,703 |
| ARKQ | XPEV | XPENG | 97,697 |
| ARKQ | VUZI | VUZIX | 32,182 |
| ARKQ | BLDE | BLADE AIR MOBILITY | 44,068 |
| ARKW | COIN | COINBASE GLOBAL | 11,761 |
| ARKW | EDR | ENDEAVOR GROUP | 177,885 |
| ARKW | VCYT | VERACYTE | 50,910 |
| ARKW | ROKU | ROKU | 7,188 |
| ARKX | AVAV | AEROVIRONMENT | 16,273 |
| ARKX | GRMN | GARMIN | 8,728 |
| ARKX | MYNA | MYNARIC | 4,707 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Contact [email protected] for any questions or corrections.








